This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Transplantation, Other  • Neurology  • Articles for Residents  • Alert me on articles by topic

Arch Ophthalmol. 2001;119:721-726.

Objectives  To quantify the risk of Creutzfeldt-Jakob disease (CJD) among cornea donors, evaluate supplemental screening strategies, and address concerns about the adequacy of current methods of screening tissue donors in the United States.

Methods  Reported data on deaths due to CJD and from all causes were used to estimate the rate of CJD among cornea donors. The impact of increased screening on risk of CJD and donor supply was evaluated.

Results  Only 1.3 of the approximately 45 000 cornea donors in the United States each year might be expected to have CJD. Most of the estimated risk (91%) is due to preclinical (asymptomatic) disease and therefore could not be eliminated by screening for signs or symptoms. If only the highest-risk age group (60 to 69 years) were screened and specificity were 90%, more than 21 000 otherwise acceptable donors would incorrectly be excluded over a period of 17.5 years to correctly exclude a single donor with symptomatic CJD.

Conclusions  Currently, the risk of CJD transmission following cornea transplantation is remarkably low. Screening for symptoms of CJD would have minimal impact on safety, but would reduce donor supply and likely result in many patients not receiving needed treatment.

Robert H. Kennedy, MD, PhD, MBA; R. Nick Hogan, MD, PhD; Paul Brown, MD; Edward Holland, MD; Richard T. Johnson, MD; Walter Stark, MD; Joel Sugar, MD
From the Health Group, Exponent, Inc, Menlo Park, Calif (Dr Kennedy); Department of Ophthalmology, The University of Texas Southwestern Medical Center at Dallas (Dr Hogan); The Laboratory of Central Nervous System Studies, The National Institutes of Neurological Diseases and Stroke, Washington, DC (Dr Brown); Department of Ophthalmology, The University of Minnesota, Minneapolis (Dr Holland); Departments of Neurology (Dr Johnson) and Ophthalmology (Dr Stark), The Johns Hopkins University, Baltimore, Md; and Department of Ophthalmology, The University of Illinois, Chicago (Dr Sugar). Dr Holland is now with the Cincinnati Eye Institute and the University of Cincinnati, Cincinnati, Ohio.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Qualifications to the Report of a New Case of Creutzfeldt-Jakob Disease in the Recipient of a Corneal Transplant
Hogan et al.
Arch Neurol 2003;60:293-294.
FULL TEXT  

Prion Protein Accumulation in Eyes of Patients with Sporadic and Variant Creutzfeldt-Jakob Disease
Head et al.
IOVS 2003;44:342-346.
ABSTRACT | FULL TEXT  

Papillary Adenocarcinoma of the Iris Transmitted by Corneal Transplantation
McGeorge et al.
Arch Ophthalmol 2002;120:1379-1383.
FULL TEXT  

Cornea procurement from very old donors: post organ culture cornea outcome and recipient graft outcome
Gain et al.
Br. J. Ophthalmol. 2002;86:404-411.
ABSTRACT | FULL TEXT